<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165102/" ref="ordinalpos=1116&amp;ncbi_uid=3451051&amp;link_uid=PMC3165102" image-link="/pmc/articles/PMC3165102/figure/F1/" class="imagepopup">Figure 1. Schematic representation of TGF-β and Hedgehog (Hh) <span class="highlight" style="background-color:">signaling</span> in cancer.  From: The TGF-?/SMAD/GLI2 <span class="highlight" style="background-color:">signaling</span> axis in cancer progression and metastasis. </a></div><br /><div class="p4l_captionBody">TGF-β ligand activation of specific cell surface serine-threonine kinase receptors activates the SMAD cascade, resulting in transcriptional activation of the GLI2 gene. GLI2 protein may either regulate target gene expression and exert pro-oncogenic activities downstream of TGF-β signaling or may contribute to Hedgehog (Hh)-driven signaling which occurs via Smoothened (SMO) activation in the primary cilium following Hh binding to the pathway inhibitory receptor Patched-1 (PTCH1).</div></div>